Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

175
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
175
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Hazard Ratio01:12

Hazard Ratio

110
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
110
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.3K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.3K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

121
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
121

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.

American journal of preventive cardiology·2026
Same author

Characteristics of Crowdfunding Campaigns for Proton Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

TRIPLETE But Incomplete? Accounting for Post-Progression Therapy When Interpreting Overall Survival.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Nonparametric estimation of the total treatment effect with multiple outcomes in the presence of terminal events.

Biometrics·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A versatile multi-components mixed model for bacterial-Genome Wide association studies.

Nature communications·2026

Related Experiment Video

Updated: Jun 21, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

484

Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials.

Alexander D Sherry, Pavlos Msaouel, Avital M Miller

    Medrxiv : the Preprint Server for Health Sciences
    |July 9, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Bayesian early stopping rules significantly improve phase III oncology trial efficiency by reducing patient enrollment and costs. This method preserves trial interpretation while accelerating the approval of effective therapies.

    More Related Videos

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
    00:04

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

    Published on: September 20, 2019

    10.6K
    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
    09:32

    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

    Published on: February 8, 2018

    14.6K

    Related Experiment Videos

    Last Updated: Jun 21, 2025

    Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
    08:36

    Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

    Published on: April 19, 2024

    484
    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
    00:04

    A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

    Published on: September 20, 2019

    10.6K
    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
    09:32

    Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

    Published on: February 8, 2018

    14.6K

    Area of Science:

    • Clinical Trials Methodology
    • Biostatistics
    • Oncology Research

    Background:

    • Improving the efficiency of phase III trials is crucial for reducing costs and accelerating the approval of new therapies.
    • Current interim assessment methods may not fully optimize trial efficiency or patient benefit.
    • Bayesian statistical methods offer a potential alternative for early stopping rules in clinical trials.

    Purpose of the Study:

    • To evaluate the hypothesis that in silico Bayesian early stopping rules enhance the efficiency of phase III oncology trials.
    • To compare the efficiency of Bayesian early stopping rules against original frequentist analyses.
    • To assess whether Bayesian rules compromise the overall interpretation of trial outcomes.

    Main Methods:

    • A cross-sectional analysis of 230 randomized phase III oncology trials (184,752 participants).
    • Individual patient-level data were reconstructed from Kaplan-Meier curves.
    • Simulated trial accruals (100 times per trial) using published outcomes, varying only accrual dynamics.

    Main Results:

    • Bayesian early stopping criteria were met in 54% of simulations.
    • Bayesian interim analysis demonstrated high predictive accuracy for trial outcomes (AUC, 0.91).
    • Bayesian rules reduced patient enrollment by an estimated 11% (20,543 patients) and saved an estimated $851 million.

    Conclusions:

    • Bayesian interim analysis can improve randomized trial efficiency by reducing enrollment needs without compromising interpretation.
    • Increased utilization of Bayesian interim analysis can lower late-phase trial costs and expedite effective therapy approvals.
    • This approach mitigates patient exposure to disadvantageous randomizations and accelerates the availability of efficacious treatments.